Sabbadini Gastone, Ciaccheri Mauro, Castelli Gabriele, Sinagra Gianfranco, Di Lenarda Andrea
Struttura Complessa di Cardiologia, Ospedali Riuniti, Piazza Ospedale, 1 34100 Trieste.
Ital Heart J Suppl. 2002 Aug;3(8):804-11.
Both beta-blockers as well as positive inotropic drugs may be indicated for the treatment of patients with advanced or refractory heart failure. When tolerated, beta-blocker therapy is able to counteract the adverse biologic effects produced by the chronic activation of the sympathetic nervous system and, therefore, to delay the progression of the disease. Conversely, although the long-term administration of positive inotropic agents is not recommended, these drugs may be required to face episodes of acute hemodynamic deterioration, which frequently occur in patients who are so severely impaired. Beta-blocker and positive inotropic therapies are currently viewed as alternative strategies for the management of severe heart failure patients. However, both the theoretical background and preliminary clinical evidences about the combined use of these two drug classes are suggestive of the potential for cumulative benefits and of the mutual attenuation of deleterious effects.
β受体阻滞剂和正性肌力药物均可用于治疗晚期或难治性心力衰竭患者。在耐受的情况下,β受体阻滞剂治疗能够抵消交感神经系统慢性激活所产生的不良生物学效应,从而延缓疾病进展。相反,虽然不建议长期使用正性肌力药物,但对于严重心功能不全患者经常出现的急性血流动力学恶化情况,可能需要使用这些药物。目前,β受体阻滞剂和正性肌力药物疗法被视为治疗严重心力衰竭患者的替代策略。然而,关于这两类药物联合使用的理论背景和初步临床证据均表明,联合使用可能具有累积益处,且能相互减轻有害作用。